<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742816</url>
  </required_header>
  <id_info>
    <org_study_id>CCTG 605s</org_study_id>
    <nct_id>NCT04742816</nct_id>
  </id_info>
  <brief_title>Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients</brief_title>
  <official_title>Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients Sub-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Will use a subset of the main study cohort of transgender or non-binary individuals to&#xD;
      evaluate the relationships between self-reported exogenous hormone use, endogenous hormone&#xD;
      values, renal biomarkers, drug levels and directly measured renal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This cross-sectional sub-study will use a subset of the main study cohort of transgender (TG)&#xD;
      or non-binary (NB) individuals to evaluate the relationships between self-reported exogenous&#xD;
      hormone use, endogenous hormone values (serum estradiol, estrone, free/total testosterone),&#xD;
      renal biomarkers, drug levels (measured by tenofovir diphosphate, TFV-DP, and emtricitabine&#xD;
      triphosphate, FTC-TP, on dried blood spot cards and urine) and directly measured renal&#xD;
      function (iohexol clearance).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>iohexol</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Iohexol clearance</measure>
    <time_frame>Day 1</time_frame>
    <description>Rate of clearance (mL/min) of iohexol from the body after a small dose is administered subcutaneously. Iohexol clearance is the gold standard for measuring kidney function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentration of tenofovir</measure>
    <time_frame>Day 1</time_frame>
    <description>Tenofovir concentrations in blood and blotted on dried blood spot cards.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Transgender</condition>
  <condition>Renal Function</condition>
  <condition>Hormone Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>Iohexol injection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The research pharmacist will prepare the iohexol injection in a 1cc tuberculin syringe, consisting of 0.5cc sterile water for injection (SWFI) and 0.5cc iohexol (Omnipaque 300). The study coordinator/personnel (licensed RN) will inject the iohexol dose into the subcutaneous tissue on the opposite arm used for blood sampling; the time will be recorded. The participant will be monitored for adverse events 30 minutes post iohexol administration at the AVRC. If the participant has not had any adverse event within 30 minutes, they will be asked to leave the AVRC and return within 2 hours and 55 minutes post Iohexol injection for lab collection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>IHX-CL measurements</intervention_name>
    <description>The distribution of measured IHX-CL values and other continuous variables will be assessed to ensure a parametric distribution.</description>
    <arm_group_label>Iohexol injection</arm_group_label>
    <other_name>OMNIPAQUE</other_name>
    <other_name>Iohexol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Iohexol clearance measurement</description>
    <arm_group_label>Iohexol injection</arm_group_label>
    <other_name>OMNIPAQUE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-uninfected&#xD;
&#xD;
          -  Identifying as transgender or nonbinary (TG/NB)&#xD;
&#xD;
          -  Age ≥ 18 years (adult)&#xD;
&#xD;
          -  At risk of acquiring HIV&#xD;
&#xD;
          -  Calculated creatinine clearance (CRCL) ≥ 60 mL/minute&#xD;
&#xD;
          -  Taking emtricitabine/tenofovir alafenamide&#xD;
&#xD;
          -  Willing to receive a small dose of iohexol&#xD;
&#xD;
          -  Willing to provide 30 mL blood and a urine sample&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to iohexol&#xD;
&#xD;
          -  Use of concurrent medications that may interfere with iohexol such as metformin,&#xD;
             amiodarone or beta-blockers&#xD;
&#xD;
          -  Anuric or unable to produce 30 mL of urine&#xD;
&#xD;
          -  Other condition that, in the opinion of the investigator, would put the participant at&#xD;
             risk, complicate interpretation of study outcome data, or would otherwise interfere&#xD;
             with participation or achieving the study objectives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nimish Patel, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego AntiViral Research Center (AVRC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah B Burke, MPH</last_name>
    <phone>619-543-8207</phone>
    <email>lbburke@health.ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen K Chow, BS</last_name>
    <phone>619-543-5320</phone>
    <email>kkchow@health.ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC San Diego AntiViral Research Center (AVRC)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah B Burke, MPH</last_name>
      <phone>619-543-8207</phone>
      <email>lbburke@health.ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Helene T Le</last_name>
      <phone>619-543-3116</phone>
      <email>helenele@health.ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nimish Patel, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Nimish Patel</investigator_full_name>
    <investigator_title>Assoc Prof Clinical</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

